CV Sciences (CVSI) Total Debt (QoQ) (2013 - 2026)
CV Sciences (CVSI) Total Debt (QoQ) (2013 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | CV Sciences | 3.90 Mn | 3.63 Mn | 1.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -75.00% |
| Mar 31, 2026 | -95.63% |
| Dec 31, 2025 | 72.67% |
| Sep 30, 2025 | -22.42% |
| Jun 30, 2025 | -2.92% |
| Mar 31, 2025 | 87.30% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 123.74% |
| Sep 30, 2020 | -12.49% |
| Mar 31, 2018 | -46.33% |
| Dec 31, 2017 | 91.97% |
| Sep 30, 2017 | -15.68% |
| Jun 30, 2017 | 87.93% |
| Mar 31, 2017 | -10.75% |
| Dec 31, 2016 | -69.12% |
| Sep 30, 2016 | 12.78% |
| Jun 30, 2016 | 185.10% |
| Mar 31, 2016 | 224.36% |
| Dec 31, 2013 | 29.77% |
| Sep 30, 2013 | 29.25% |